{
  "schema": "http://google-preview.miscsubjects.com/schemas/jarticle.json",
  "status": "published",
  "slug": "tirzepatide-glp1-agonists",
  "title": "tirzepatide glp1 agonists",
  "kind": "standard",
  "summary": "Evidence is being populated by Grok web",
  "created": "2026-06-29T17:45:36.023Z",
  "body": [
    "## Overview\nEvidence is being populated by Grok web search."
  ],
  "facts": {
    "converted_from": "markdown",
    "original_updated": "2026-06-29T17:45:54.298Z",
    "register": "standard",
    "category": null
  },
  "sources": [
    {
      "id": "s1",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40746703/",
      "title": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration",
      "quote": "A dose-dependent tirzepatide was superior to placebo and GLP-1 RAs in weight reduction. However, the lean mass reduction and tolerability require further investigation.",
      "summary": "2025 meta-analysis of 6 RCTs (6266 subjects) showing tirzepatide (5-15mg) superior for weight loss vs placebo/GLP-1 RAs; high-certainty for ≥15% loss.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:45:36.162Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "genesis",
      "hash": "0bc10e667490a0d1de52db56c7f9bc6edd4628dab777683966ad8fb5aa31ffbe",
      "quote_sha256": "72db5087da8d14daf80a7f4d743fcbdd784cb386875a3a4bb37bde5f1200bd5c"
    },
    {
      "id": "s2",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42119587/",
      "title": "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial",
      "quote": "We evaluated the efficacy and safety of continuing tirzepatide at the maximum tolerated dose (MTD) or lowering the dose to 5 mg compared with placebo.",
      "summary": "2026 Lancet phase 3 trial on tirzepatide for weight maintenance in obesity.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:45:36.162Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "0bc10e667490a0d1de52db56c7f9bc6edd4628dab777683966ad8fb5aa31ffbe",
      "hash": "8f9696ced4d3722d12ef2047cdc36535115e6cec92eb6498ecc410a89fc2c0fc",
      "quote_sha256": "c25f8fac32fb17d050812ae64d9aa2731b213814b3d1dcb82449b66184042246"
    },
    {
      "id": "s3",
      "type": "clinical_trial",
      "url": "https://clinicaltrials.gov/study/NCT06820281",
      "title": "Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes",
      "quote": "This mechanistic study will define mechanisms by which GLP1-GIP co-agonism may uniquely provide clinical benefits in T1D during the fasting and fed states.",
      "summary": "2025 mechanistic trial on tirzepatide (GLP-1/GIP agonist) effects in type 1 diabetes.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:45:36.162Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "8f9696ced4d3722d12ef2047cdc36535115e6cec92eb6498ecc410a89fc2c0fc",
      "hash": "167a284b48b2506597dcd0895fe37a97fc5a85d7d4f10fc652f45ef99360643e",
      "quote_sha256": "7481a04538375a8c400150f7221a401552551fe47a03c888c0be22cdf1ee5630"
    },
    {
      "id": "s4",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40353578/",
      "title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity",
      "quote": "Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight.",
      "summary": "2025 SURMOUNT-5 trial: tirzepatide superior to semaglutide for weight loss in obesity without diabetes.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:45:36.162Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "167a284b48b2506597dcd0895fe37a97fc5a85d7d4f10fc652f45ef99360643e",
      "hash": "3fcae7a5d9dce8b01400f3fddfd4cf2af5d76d57cb7e347371a7489bb63d625b",
      "quote_sha256": "63e1eed5a123b6cf41f50f80ab69ac8d518b5860e6383673d390255af30aec65"
    },
    {
      "id": "s5",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41264593/",
      "title": "Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Clinical Trial",
      "quote": "Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.",
      "summary": "2026 phase 2 trial showing tirzepatide benefits in T1D with obesity.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:45:36.162Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "3fcae7a5d9dce8b01400f3fddfd4cf2af5d76d57cb7e347371a7489bb63d625b",
      "hash": "3d44a8cc318c688eecec61496d7e0d2383560fd7f27b5d7e4e7227a9900a2699",
      "quote_sha256": "8384b1e0c2332883eefe85f7f066b3c11054aefed10e3a439dfd9f8bc718d481"
    },
    {
      "id": "s6",
      "type": "review",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41761267/",
      "title": "Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis",
      "quote": "These findings suggest that tirzepatide provides cardiovascular benefit at least comparable to established GLP-1RAs, supporting its emerging role in cardiovascular risk reduction in T2D.",
      "summary": "Systematic review and network meta-analysis of RCTs showing tirzepatide reduces MACE, CV mortality, all-cause mortality, non-fatal MI and stroke vs placebo, comparable to GLP-1RAs.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:45:53.437Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "3d44a8cc318c688eecec61496d7e0d2383560fd7f27b5d7e4e7227a9900a2699",
      "hash": "8ee4366358b7274f085aa6b39475f0e69642e72bd24b4f5825e4f569c83da422",
      "quote_sha256": "c71a8969e3a72eacedcab1234ee5318708326d0c46790817d03880e1dc0279d2"
    },
    {
      "id": "s7",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42168641/",
      "title": "Causes and consequences of discontinuation of GLP1RAs and tirzepatide",
      "quote": "In this Review, we discuss common reasons for GLP1R agonist and tirzepatide discontinuation and examine available evidence related to potential cardiometabolic ...",
      "summary": "Review on discontinuation reasons for GLP-1RAs including tirzepatide and cardiometabolic evidence.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:45:53.437Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "8ee4366358b7274f085aa6b39475f0e69642e72bd24b4f5825e4f569c83da422",
      "hash": "0371dcd0b18e6afd6695db514160cfd9aa4c24c546e658dc2ae6a5321560e678",
      "quote_sha256": "1cd36cc8c8fd9bb65e7cd12f7cfe564defbbe439eddc10ce30400c6859490ad6"
    },
    {
      "id": "s8",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41655764/",
      "title": "Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists",
      "quote": "Among patients with T2D taking a GLP-1 RA, tirzepatide was associated with lower risks of retinal complications, need for vision-saving ...",
      "summary": "Study finding lower retinal complication risks with tirzepatide vs other GLP-1 RAs in T2D patients.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:45:53.437Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "0371dcd0b18e6afd6695db514160cfd9aa4c24c546e658dc2ae6a5321560e678",
      "hash": "f48a6b4930245e0cbba1fa071ffd6911cb87d527571210dc93b88f65ff1cae64",
      "quote_sha256": "e2267988b0881dee4b9fb48270c8815169fa3610502baee18c512bba1e25efc1"
    },
    {
      "id": "s9",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41936548/",
      "title": "Weight Loss With GLP-1 Agonists in Nondiabetic Adults",
      "quote": "Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes.",
      "summary": "Analysis showing tirzepatide superior for weight loss in nondiabetic adults compared to other GLP-1 agonists.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:45:53.437Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "f48a6b4930245e0cbba1fa071ffd6911cb87d527571210dc93b88f65ff1cae64",
      "hash": "d7ea3b96d9412a96a0034ce9dee3ef7ee725221cd2174c0d90daf51b66336bbd",
      "quote_sha256": "71633aad767378b74c3588c27bf44226cfc77c84403b57c83537f1cf10c7bacb"
    }
  ],
  "type": "article",
  "updated": "2026-10-08T11:49:30.728Z",
  "version": 1,
  "hash": "cc205d147ba4417ec5e972bbbe2b1339e9921f4ede134b79c2aeb39a457a317c",
  "styling": {
    "scope": "shared",
    "how": "no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH http://google-preview.miscsubjects.com/api/jarticles/theme changes them.",
    "widget_style": {
      "what": "every widget may carry style: {…}; these are the only keys it reads",
      "rotate": "degrees, a number",
      "offset_x": "pixels, a number",
      "offset_y": "pixels, a number",
      "pulse": "true to pulse"
    },
    "theme": {
      "color": {
        "page_bg": "#f5f5f7",
        "sheet_bg": "#ffffff",
        "ink": "#1d1d1f",
        "soft": "#424245",
        "muted": "#6e6e73",
        "dim": "#86868b",
        "line": "#d2d2d7",
        "accent": "#0071e3",
        "accent_soft": "rgba(0,113,227,0.08)",
        "link": "#0066cc",
        "selection": "rgba(0,113,227,0.18)",
        "widget_bg": "#f5f5f7",
        "widget_border": "#d2d2d7",
        "card_bg": "#ffffff",
        "code_bg": "#f5f5f7",
        "json_bg": "#161b19",
        "json_ink": "#e6e1d4",
        "json_key": "#7fd3c3",
        "json_string": "#e9c46a",
        "json_number": "#f4a261",
        "json_bool": "#c792ea",
        "json_null": "#928d7e",
        "json_punct": "#6b6759",
        "json_bar": "#0e1512",
        "kind_badge_bg": "#0e6e60",
        "kind_badge_ink": "#ffffff"
      },
      "color_dark": {
        "page_bg": "#000000",
        "sheet_bg": "#1d1d1f",
        "ink": "#f5f5f7",
        "soft": "#d2d2d7",
        "muted": "#a1a1a6",
        "dim": "#86868b",
        "line": "#424245",
        "accent": "#2997ff",
        "accent_soft": "rgba(41,151,255,0.12)",
        "link": "#2997ff",
        "selection": "rgba(41,151,255,0.25)",
        "widget_bg": "#2c2c2e",
        "widget_border": "#424245",
        "card_bg": "#1d1d1f",
        "code_bg": "#2c2c2e",
        "json_bg": "#0a0d0c",
        "json_ink": "#e6e1d4",
        "json_key": "#7fd3c3",
        "json_string": "#e9c46a",
        "json_number": "#f4a261",
        "json_bool": "#c792ea",
        "json_null": "#757062",
        "json_punct": "#5d665f",
        "json_bar": "#060807",
        "kind_badge_bg": "#4fc1ab",
        "kind_badge_ink": "#0b0f0d"
      },
      "font": {
        "display": "-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
        "body": "-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
        "mono": "ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
        "google_fonts": ""
      },
      "size": {
        "body": "17px",
        "small": "17px",
        "eye": "17px",
        "lead": "17px",
        "h1": "52px",
        "h2": "34px",
        "h3": "22px",
        "byline": "17px",
        "h1_measure": "none",
        "code": "17px",
        "json": "17px",
        "widget_title": "17px"
      },
      "leading": {
        "body": "1.7",
        "head": "1.18",
        "lead": "1.5",
        "json": "1.6"
      },
      "weight": {
        "display": "700",
        "head": "700",
        "body": "400",
        "strong": "700",
        "eye": "700"
      },
      "tracking": {
        "eye": "0.14em",
        "display": "-0.03em",
        "body": "-0.006em",
        "badge": "0.08em"
      },
      "layout": {
        "sheet_width": "1000px",
        "text_width": "880px",
        "gutter": "16px",
        "sheet_padding": "56px 64px 64px",
        "sheet_padding_mobile": "24px 18px 40px",
        "sheet_margin": "28px auto 72px",
        "block_gap": "1.15em",
        "widget_gap": "28px",
        "grid_gap": "14px"
      },
      "border": {
        "sheet": "0px solid",
        "sheet_radius": "30px",
        "widget": "1px solid",
        "widget_radius": "24px",
        "card_radius": "24px",
        "badge_radius": "999px",
        "rule": "1px solid",
        "code_radius": "18px",
        "accent_bar": "3px"
      },
      "shadow": {
        "sheet": "0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
        "widget": "none",
        "card_hover": "0 10px 28px -16px rgba(28,27,23,0.35)"
      },
      "motion": {
        "hover": "160ms ease"
      }
    }
  },
  "page": "http://google-preview.miscsubjects.com/a/tirzepatide-glp1-agonists",
  "json": "http://google-preview.miscsubjects.com/a/tirzepatide-glp1-agonists.json",
  "markdown": "http://google-preview.miscsubjects.com/a/tirzepatide-glp1-agonists.md",
  "theme": "http://google-preview.miscsubjects.com/article-theme.json",
  "calls": [
    {
      "what": "this article as a page (no key)",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/a/tirzepatide-glp1-agonists",
      "headers": {}
    },
    {
      "what": "this article as its object (no key)",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/a/tirzepatide-glp1-agonists.json",
      "headers": {}
    },
    {
      "what": "this article as Markdown (no key)",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/a/tirzepatide-glp1-agonists.md",
      "headers": {}
    },
    {
      "what": "the object with its hash, drafts too",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "one piece and that piece’s hash",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists/at?path=facts",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "grep: every key or value that matches, with the path to change it",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists/grep?q=owner",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "change pieces (set, merge, delete, append, insert, move); if-match is the hash",
      "method": "PATCH",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json",
        "if-match": "<hash from the read>"
      },
      "body": {
        "ops": [
          {
            "op": "set",
            "path": "facts.example",
            "value": 1
          }
        ]
      }
    },
    {
      "what": "replace the whole object",
      "method": "PUT",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json",
        "if-match": "<hash>"
      },
      "body": {
        "slug": "tirzepatide-glp1-agonists",
        "title": "…"
      }
    },
    {
      "what": "fetch every source, hash what came back and check the quote is in it",
      "method": "POST",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/tirzepatide-glp1-agonists/verify",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json"
      },
      "body": {}
    },
    {
      "what": "an Obsidian-style command",
      "method": "POST",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/cli",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json"
      },
      "body": {
        "command": "backlinks",
        "file": "tirzepatide-glp1-agonists"
      }
    }
  ]
}